SG/CALL/ROCHE GS/390/0.1/21.06.24 Stock

Warrant

DE000SV656E5

Market Closed - Deutsche Boerse AG 03:37:22 2024-05-10 pm EDT
0.001 EUR 0.00% Intraday chart for SG/CALL/ROCHE GS/390/0.1/21.06.24
Current year-98.78%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change Volume
24-05-10 0.001 0.00% 0
24-05-09 0.001 0.00% 0
24-05-08 0.001 0.00% 0
24-05-07 0.001 0.00% 0
24-05-06 0.001 0.00% 0

Delayed Quote Deutsche Boerse AG

Last update May 10, 2024 at 03:37 pm EDT

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Société Générale Société Générale
WKN SV656E
ISINDE000SV656E5
Date issued 2023-06-07
Strike 390 CHF
Maturity 2024-06-21 (41 Days)
Parity 10 : 1
Emission price 0.23
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.23
Lowest since issue 0.001
Delta0.02x
Omega 11.85
Premium73.42x
Gearing606.53x
Moneyness 0.5772
Difference Strike 164.9 CHF
Difference Strike %+42.28%
Spread 0.074
Spread %98.67%
Intrinsic value 0.000000

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
225.1 CHF
Average target price
279.4 CHF
Spread / Average Target
+24.12%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW